Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation with Decitabine-containing Regimen in Myelodysplastic Syndromes and Myelodysplastic Syndromes Transformed Acute Myeloid Leukemia / 中国实验血液学杂志

OBJECTIVE@#To evaluate the efficacy and safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with decitabine (Dec)-conditioning regimen in the treatment of myelodysplastic syndrome (MDS) and MDS transformed acute myeloid leukemia (MDS-AML).@*METHODS@#The characteristics and efficacy data of 93 patients with MDS and MDS-AML who received allo-HSCT in our center from April 2013 to November 2021 were retrospectively analyzed. All patients were administered by myeloablative conditioning regimen containing Dec (25 mg/m2 /d×3 d).@*RESULTS@#Among the 93 patients, 63 males and 30 females, were diagnosed as MDS（n ＝77）, MDS-AML（n ＝16）. The incidence of I/II grade regimen-related toxicity (RRT) was 39.8%, and III grade RRT was only found in 1 patient (1%). Neutrophil engraftment was successful in 91 (97.8%) patients after a median neutrophil engraftment time of 14 (9-27) days; Successful platelet engraftment was achieved in 87 (93.5%) patients, with a median engraftment time of 18 (9-290) days. The incidence of acute graft versus host disease（aGVHD） and grade III-IV aGVHD was 44.2% and 16.2%, respectively. The incidence of chronic graft versus host disease（cGVHD） and moderate-to-severe cGVHD was 59.5% and 37.1%, respectively. Of the 93 patients, 54 (58%) developed posttransplant infections, among which lung infection (32.3%) and bloodstream infection (12.9%) were the most common. The median follow-up after transplantation was 45 (0.1-108) months. The 5-year overall survival (OS) rate, disease-free survival (DFS) rate, treatment-related mortality, and cumulative incidence of relapse were 72.7%, 68.4%, 25.1%, and 6.5%, respectively. And the 1-year graft-versus-host disease/relapse-free survival rate was 49.3%. The patients in different group of relative high-risk prognostic scoring or low-risk prognostic scoring, with or without poor-risk mutation(s), with mutations number ≥3 or <3 had similar 5-year OS rate (more than 70%). Multivariate analysis showed that the incidence of grade III-IV aGVHD was the independent risk factor affecting OS（P =0.008）and DFS (P =0.019).@*CONCLUSION@#Allo-HSCT with Dec-conditioning regimen is feasible and effective in the treatment of patients with MDS and MDS-AML, especially those in high prognostic risk and with poor-risk mutations.

Humanized anti-CD25 monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation / 中华血液学杂志

Objective: To investigate the efficacy of humanized anti-CD25 monoclonal antibody for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Methods: A total of 64 patients with SR-aGVHD between June 2019 and October 2020 in Suchow Hopes Hematology Hospital were enrolled in this study. Humanized anti-CD25 monoclonal antibodies 1 mg·kg(-1)·d(-1) were administered on days 1, 3, and 8, and then once per week according to the disease progression. Efficacy was assessed at days 7, 14, and 28 after humanized anti-CD 25 treatment. Results: Of the 64 patients with a median age of 31 (15-63) years, 38 (59.4%) were male and 26 (40.6%) were female. The overall response (OR) rate of the humanized CD25 monoclonal antibody in 64 patients with SR-aGVHD on days 7, 14, and 28 were 48.4% (31/64), 53.1% (34/64), and 79.7% (51/64), respectively. Liver involvement is an independent risk factor for poor efficacy of humanized CD25 monoclonal antibody for SR-aGVHD at day 28 (OR=9.588, 95% CI 0.004-0.291, P=0.002). The median follow-up time for all patients was 17.1 (0.2-50.8) months from the start of humanized CD25 monoclonal antibody therapy. The 1- and 2-year OS rates were 63.2% (95% CI 57.1% -69.3%) and 52.6% (95% CI 46.1% -59.1%), respectively. The 1- and 2-year DFS rates were 58.4% (95% CI 52.1% -64.7%) and 49.8% (95% CI 43.4% -56.2%), respectively. The 1- and 2-year NRM rates were 28.8% (95% CI 23.1% -34.5%) and 32.9% (95% CI 26.8% -39.0%), respectively. The results of the multifactorial analysis showed that liver involvement (OR=0.308, 95% CI 0.108-0.876, P=0.027) and GVHD grade Ⅲ/Ⅳ (OR=9.438, 95% CI 1.211-73.577, P=0.032) were independent risk factors for OS. Conclusion: Humanized CD25 monoclonal antibody has good efficacy and safety for SR-aGVHD. This study shows that SR-aGVHD with pretreatment grade Ⅲ/Ⅳ GVHD and GVHD involving the liver has poor efficacy and prognosis and requires early intervention.

Advances in Allogeneic Chimeric Antigen Receptor T Cells / 中国医学科学院学报

Autologous chimeric antigen receptor(CAR)T-cell therapy has improved the prognosis of hematological malignancies.Nevertheless,allogeneic CAR-T cells have potential advantages over the autologous approach available on the market.However,allogeneic CAR-T cells may cause life-threatening graft-versus-host disease(GVHD)or be rapidly eliminated by the host immune system.In this review,we analyze the different sources of T cells for optimal allogeneic CAR-T cell therapy,describe the different approaches,and introduce the gene editing measures to produce allogeneic CAR-T cells with limited potential for GVHD and improved anti-tumor effect.

Doença do Enxerto-versus-hospedeiro ocular: Revisão / Graft-versus-Host Disease: Review

Resumo Doença do Enxerto-versus-hospedeiro (do inglês Graft-versus-Host Disease - GVHD) é uma complicação importante e com altas taxas de morbidade e mortalidade nos pacientes submetidos ao transplante alogênico de células-tronco hematopoiéticas. O acometimento ocular, denominado GVHD ocular, pode acometer todas as estruturas dos olhos, porém a unidade lacrimal (glândulas lacrimais e superfície ocular) é o principal alvo da resposta inflamatória mediada por células T doadas. O desenvolvimento de doença do olho seco grave é a principal manifestação clínica ocular, e a associação de diversas opções terapêuticas se faz necessário. O objetivo desta revisão é descrever as manifestações clínicas, os critérios diagnósticos, o impacto na qualidade de vida, o tratamento atual e as perspectivas desta doença, que precisa de um acompanhamento multidisciplinar.

Abstract Graft-versus-host Disease (GVHD) is a major complication with high morbidity and mortality rates on patients undergoing hematopoietic stem cell transplantation. The ocular involvement, named ocular GVHD, may affect all structures of the eyes, but the lacrimal unit (lacrimal glands and ocular surface) is the main target of the inflammatory response mediated by the donor T cells. The development of dry eye disease is the main clinical ocular manifestation, and the association of a variety of therapeutics options is necessary. The aim of the review is to describe the clinical manifestations, diagnostic criteria, impact in quality of life, the current treatment and future perspectives of this disease that demands a multidisciplinary follow-up.

Desafíos terapéuticos en la enfermedad injerto contra huésped / Therapeutic challenges in graft versus host disease

La enfermedad injerto contra huésped es una entidad en la cual las células inmunológicas competentes de un tejido injertado reconocen y dañan antígenos presentes en el receptor del trasplante, que es incapaz de defenderse de ellas. Es una complicación frecuente del trasplante alogénico de médula ósea, y con menor frecuencia se produce luego de trasplantes de órganos sólidos o transfusiones de hemoderivados no irradiados. Se comunica el caso de una paciente de sexo femenino de 23 años, con leucemia linfoblástica aguda.y trasplante alogénico de médula ósea, que presentó una enfermedad injerto contra huésped con compromiso cutáneo y gastrointestinal dependiente de corticoides, con mejoría de los signos y síntomas cutáneos luego del tratamiento con infliximab y fotoféresis extracorpórea. (AU)

Graft versus host disease is an entity in which competent grafted immune cells recognize and damage tissue antigens present in the transplant recipient, who is unable to defend from them. It is one of the most serious complications in patients undergoing allogeneic bone marrow transplantation, although less frequently it may be associated with solid organ transplants or transfusions of not irradiated blood products. We report the case of a 23 year-old patient with acute lymphoblastic leukemia and allogeneic bone marrow transplantation, that presented graft versus host disease with skin and gastrointestinal involvement, dependent on corticosteroids, that showed improvement in signs and skin symptoms after treatment with infliximab and extracorporeal photopheresis. (AU)

Acute and chronic Graft-versus-host disease after hematopoietic stem cell transplantation / Doença do enxerto contra o hospedeiro aguda e crônica após transplante de células-tronco hematopoiéticas

ABSTRACT graft-versus-host disease (GVHD) is one of the main complications of hematopoietic stem cell transplantation, affecting about 50% to 80% of the patients. Acute GVHD and its clinical manifestations are discussed in this article, as well as the new NIH criteria for the diagnosis and classification of chronic GVHD. Therapy for both chronic and acute GVHD is an important field of discussion, as there is no proven superiority for the majority of therapies used after primary treatment has failed. Hence, this review is meant to be a useful consultation tool for hematologists dealing with this complex transplantation procedure complication.

RESUMO A doença do enxerto contra hospedeiro (DECH) é uma das principais complicações do transplante de células-tronco Hematopoéticas, acometendo cerca de 50% a 80% dos pacientes. A DECH aguda e suas manifestações clínicas são discutidas neste artigo, bem como a classificação revisada do NIH para diagnóstico e classificação da DECH crônica. A terapêutica para DECH aguda e crônica é um importante campo de discussão uma vez que não há superioridade comprovada para a maioria das terapêuticas utilizadas após o tratamento primário. Assim, esta revisão pretende ser instrumento de consulta para hematologistas transplantadores que lidam com esta complexa complicação do procedimento.

Cutaneous graft-versus-host disease after hematopoietic stem cell transplant - a review

Abstract Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplants (allo-HSCT) associated with significant morbidity and mortality. The earliest and most common manifestation is cutaneous graft-versus-host disease. This review focuses on the pathophysiology, clinical features, prevention and treatment of cutaneous graft-versus-host disease. We discuss various insights into the disease's mechanisms and the different treatments for acute and chronic skin graft-versus-host disease.

Treatments and supportive therapies for oral manifestations of chronic graft-versus-host disease / Tratamentos e terapias de suporte para manifestações orais da doença crônica do enxerto contra hospedeiro

The aim of this study was to conduct a systematic review of treatments and therapies for oral manifestations of chronic graft-versus-host disease, aiming at improving patients' quality of life and mainly the reduction of mortality caused by graft- versus-host disease. A systematic review was carried out by two evaluators, a Dentistry professor and an undergraduate student. A selection of open-access full-text online articles, carried out on PubMed, GoPubmed, NLM Gateway, LILACS, BIREME, SciELO, IBECS, and Web of Science. The survey was completed in July 2012. Of the 1147 studies found, 52 fit the selection criteria. Patients (n = 2130) received different treatment regimens, either systemic or topical. Drugs for systemic therapy were divided into those with action on the inhibition of proliferation and/or release of T and B cells, with action on inflammatory disorders, and of immunomodulatory effect. Topical drugs were divided into their pattern of mucosal absorption and their ability to act on tissue growth factors. The analysis of articles concluded that the most used systemic drugs were Methylprednisolone and corticosteroids, and Tacrolimus and topical Cyclosporine for topical and local therapy.

O objetivo do trabalho foi realizar uma revisão sistemática sobre tratamentos e terapias de suporte para manifestações orais da doença crônica do enxerto contra hospedeiro, visando à melhoria da qualidade de vida dos pacientes e, principalmente, a redução da mortalidade causada pela doença do enxerto contra hospedeiro. A revisão sistemática foi realizada por dois examinadores, um professor e um graduando de odontologia. A seleção de acesso aberto de artigos online de texto completo, realizadas no PubMed, GoPubmed, NLM Gateway, LILACS, BIREME, SciELO, IBECS e Web of Service. A revisão foi concluída em julho de 2012. Dos 1.147 estudos encontrados, 52 se enquadraram nos critérios de seleção. Os pacientes (n = 2130) receberam diferentes tratamentos, seja de forma sistêmica ou tópica. Os medicamentos para tratamento sistêmico foram divididos entre aqueles com ação na inibição da proliferação e / ou liberação de células T e B, com ação em doenças inflamatórias, e de efeito imunomodulador. Drogas tópicas foram divididas em seu padrão de absorção da mucosa e a sua capacidade para atuar sobre os fatores de crescimento de tecidos. A análise dos artigos permitiu concluir que os medicamentos sistêmicos mais utilizados foram Metilprednisolona e corticosteróides, e Tacrolimus e Ciclosporina tópica para a terapia tópica e local.

Informe técnico sobre cobertura de triptorelina para preservación ovárica e infliximab para enfermedad de injerto contra el huésped refractario a corticoides post trasplante de progenitores hematopoyéticos en niños / Technical report on triptorelin coverage for ovarian preservation and infliximab for graft-versus-host disease in post-transplant recipients of hematopoietic progenitors in children

El Fondo Intangible Solidario de Salud solicita las evaluaciones de las tecnologías: triptorelina para preservación ovárica en mujeres que tienen indicaciones de recibir quimioterapia por câncer de mama; Infliximab para el tratamiento de la enfermedad de injerto contra el huésped refractario a corticoides post trasplante de progenitores hematopoyético en niños. Las indicaciones solicitadas para evaluación de las tecnologías triptorelina e infliximab no corresponden a la indicación terapéutica referida en ficha técnica proporcionada por la industria por lo que se desestima su evaluación para cobertura por el Seguro Integral de Salud.

A study of the Unna Boot compared with the elastic bandage in venous ulcers: a randomized clinical trial / Estudo da Bota de Unna comparado à bandagem elástica em úlceras venosas: ensaio clínico randomizado / Estudio de la Bota de Unna comparada al vendaje elástico en úlceras venosas: ensayo clínico aleatorio

AbstractObjective: to analyze the process of tissue repair in patients with venous ulcers using inelastic compression therapy (the Unna Boot), in comparison with the use of the elastic bandage.Method: a controlled randomized clinical trial in which the patients (n=18) were allocated to two groups, those who used the Unna Boot (group B) and those who used the elastic bandage (group A). The study's follow-up period was 13 weeks.Results: a significant reduction took place, at the level of 5%, in the area, in square centimeters, of the ulcers of group B (p<0.0001) throughout the treatment, and there was a tendency of group A for reduction in the area of the ulcer, in centimeters squared (p=0.06), only after the fifth week.Conclusion: the treatment with the Unna Boot presented better results in venous ulcers with areas over 10cm², and the elastic bandage with Petrolatum(r) gauze in venous ulcers below 10cm². Brazilian Clinical Trials Register: Trial (req: 195) and WHO UTN U1111-1122-5489.

ResumoObjetivo:analisar o processo de reparo tecidual de pacientes com úlcera venosa em uso da terapia compressiva inelástica (Bota de Unna), em comparação ao uso da bandagem elástica.Método:ensaio clínico controlado randomizado em que os pacientes (n=18) foram alocados em dois grupos, os que utilizavam a Bota de Unna (grupo B) e os que utilizavam a atadura elástica (grupo A). O tempo de seguimento da pesquisa foi de treze semanas.Resultados:ocorreu redução significativa, no nível de 5%, na área, em centímetros quadrados, das úlceras do grupo B (p<0,0001) ao longo de todo o tratamento, e tendência do grupo A à redução, na área da úlcera, em centímetros quadrados (p=0,06), apenas após a quinta semana.Conclusão:o tratamento com a Bota de Unna apresentou melhor resultado em úlceras venosas com áreas superiores a 10cm², e a atadura elástica com a gaze Petrolatum(r)em úlceras venosas inferiores a 10cm². Registro Brasileiro de Ensaios Clínicos: Trial (req: 195) e WHO UTN U1111-1122-5489.

ResumenObjetivo:analizar el proceso de reparación del tejido de pacientes con úlcera venosa que usan la terapia compresiva inelástica (Bota de Unna), en comparación con el uso del vendaje elástico.Método:ensayo clínico controlado aleatorio en que los pacientes (n=18) fueron designados en dos grupos, los que utilizaban la Bota de Unna (grupo B) y los que utilizaban el vendaje elástico (grupo A). El tiempo de duración de la investigación fue de trece semanas.Resultados:se constató reducción significativa, al nivel de 5%, en el área, en centímetros cuadrados, de las úlceras del grupo B (p<0,0001) a lo largo de todo el tratamiento; y tendencia del grupo A a la reducción, en el área de la úlcera, en centímetros cuadrados (p=0,06), solamente después de la quinta semana.Conclusión:el tratamiento con la Bota de Unna presentó mejor resultado en úlceras venosas con áreas superiores a 10cm², y el vendaje elástico con la gasa Petrolatum(r)en úlceras venosas inferiores a 10cm². Registro Brasileño de Ensayos Clínicos: Trial (req: 195) y WHO UTN U1111-1122-5489.

Enfermedad injerto versus huésped / Graft versus host disease

La enfermedad injerto versus huésped (EIVH) es una entidad de frecuente presentación en las personas que son intervenidas con alotrasplantes. Es inducida y mantenida por las células inmunocompetentes del injerto, que atacan los tejidos del huésped; especialmente los epitelios. El diagnóstico de la EIVH es clínico, apoyado en la histopatología, pero esta, por sí misma, no permite diagnosticar la entidad. La primera línea de tratamiento de la EIVH continúan siendo los esteroides sistémicos y ante refractariedad para estos, aparecen nuevas terapéuticas que resultan efectivas en casos reportados en la literatura, sin que aún se hayan podido definir guías de manejo para este tipo de pacientes. Se necesita realizar estudios de terapéutica en pacientes refractarios a esteroides para poder concluir al respecto.

Graft versus host disease is a condition of frequent occurrence in people who are implanted with allogeneic transplants. The diagnosis is clinical, supported by histopathology, but this, by itself does not make a diagnosis. The first line of treatment for this entity are systemic steroids. For the patient refractory to systemic steroids, new therapeutics that could be useful are reported, but not yet defined its use and none were superior to steroids. Studies are needed to define the approach to the patient refractory to steroids.

Forma aguda da doença enxerto contra o hospedeiro após transplante de fígado: Existe opção terapêutica para as formas refratárias ao tratamento com esteróides? / Acute graft versus host disease after liver transplantation: Do we have an option for treatment of steroid-refractory forms?

Background: Acute graft-versus-host disease (GVHD) usually occurs by 8 weeks after liver transplantation (LT) usually is an uncommon complication but has both high mortality and major diagnostic challenge in addition most of them are associated with resistance to steroid therapy. Objective: Discuss the pathogenesis, treatment and long-term results of Acute Graft versus Host Disease after Liver Transplantation. Methods: A PubMed search was performed to identify all reported cases of GVHD following LT. The medical subject heading GVHD disease was used in combination with LT, including adults (19 + years) and children. The bibliographies of the articles found though PubMed were then searched for further reports of GVHD. Results: We reviewed 102 cases of acute GVHD, 96 (94.1%) adults and 6 (5.8%) children. After treatment 24 (25%) adults and 3 (50%) children were alive only. As faras the treatment of GVHD is concern the therapy used in adults and in children patients was respectively : anti-thymocyte globulin + prednisolone – 19 (19.5%); interleukin-2 receptor blocker – 17 (17.5%); OKT3 – 12 (12.3%); cyclosporine – 9 (9,2% ); others – 39 (40.2%) and in children anti-thymocyte globulin – 1 (20%);anti-thymocyte globulin + prednisolone – 1 (20%); prednisolone – 1 (20%); anti-thymocyte globulin + prednisolone + interleukin-2 receptor blocker-1 (20%); not mentioned – 1.There was no standard treatment of acute GVHD for both children and adults. Conclusion: Although acute GVHD following LT is rare complication and mortality is still very high, there is no consensus for the treatment ofsteroid-refractory forms. Further researches are needed to providenew approach for treating effectively such condition.

Introdução: A forma aguda da doença do enxerto contra o hospedeiro ocorre geralmente até oito semanas após o transplante de fígado, é rara, porém tem mortalidade alta e constitui-se emum grande desafio terapêutico principalmente naqueles casos quesão resistentes ao tratamento com corticóides. Objetivo: Discutir a patogênese, tratamento e resultados a longo prazo da Forma Aguda da Doença Enxerto contra o Hospedeiro após Transplante de Fígado. Métodos: Fizemos uma pesquisa na base de dados do PubMed procurando identificar todos os casos de doença Enxerto contra o Hospedeiro após Transplante de Fígado incluindo adultos com mais de 19 anos e crianças. Resultados: Revisamos 102 casos desta doença e encontramos 96 (94,1%) adultos e 6 (5,8%) crianças. Após o tratamento, 24 (25%) adultos e 3 (50%) crianças estavam vivos. Com relação ao tratamento da doença do enxerto contra o hospedeiro em adultos e crianças encontramos respectivamente: globulina anti-timocítica + prednisolona – 19 (19,5%); bloqueador do receptor da interleucina 2 – 17 (17,5%); OKT3 – 12 (12,3%); ciclosporina – 9 (9,2%); outros – 39 (40,2%) e em crianças globulina anti-timocítica – 1 (20%); globulina antitimocítica + prednisolona – 1 (20%); prednisolona – 1 (20%); globulina anti-timocítica + prednisolona + bloqueador do receptor da interleucina 2 -1 (20%); não mencionado – 1. Conclusão: Pesquisas devem ser aprofundadas nos mecanismos que desencadeiam esta patologia. Não existe consenso para o tratamento da doença do enxerto contra o hospedeiro após o transplante de fígado naqueles doentes que são refratários ao uso de esteróides.

Immunomodulatory effect of mesenchymal stem cells

Mesenchymal stem cells (MSC) are multipotential nonhematopoietic progenitor cells capable of differentiating into multiple mesenchymal tissues. MSC are able to reconstitute the functional human hematopoietic microenvironment and promote engraftment of hematopoietic stem cells. MSC constitutively express low levels of major histocompatibility complex-I molecules and do not express costimulatory molecules such as CD80, CD86 or CD40, thus lacking immunogenicity. Furthermore, they are able to suppress T- and B-lymphocyte activation and proliferation and may also affect dendritic cell maturation. Based on these properties, MSC are being used in regenerative medicine and also for the treatment of autoimmune diseases and graft-versus-host disease. On the other hand, MSC from patients diagnosed with myelodysplastic syndromes or multiple myeloma display abnormalities, which could play a role in the physiopathology of the disease. Finally, in patients with immune thrombocytopenic purpura, MSC have a reduced proliferative capacity and a lower inhibitory effect on T-cell proliferation compared with MSC from healthy donors.

Enfermedad injerto contra huésped crónica refractaria / Refractory chronic graft versus host disease

La enfermedad injerto contra huésped (EICH) crónica es la complicación más frecuente y seria del trasplante de médula ósea alogénico. Presentamos el caso de una paciente con EICH crónica refractaria a prednisona, ciclosporina, mofetil micofenolato, irradiación ultravioleta A y psoralenos (PUVA) y rituximab.

The chronic graft-versus-host-disease (GVHD) is the most frequent and serious complication of the allogenic bone marrow transplantation. We present a patient who was refractory to prednisone, cyclosporine A, mycophenolate mofetil, ultraviolet irradiation and psoralen (PUVA), and rituximab.

Enfermedad de injerto versus huésped / Graft-versus-host disease

La enfermedad de Injerto contra Huésped (EICH) es una cuadro que se produce en algunos de los pacientes receptores de un trasplante de médula ósea, en el cual los linfocitos T inmunocompetentes del tejido trasplantado reaccionan en contra de los tejidos del receptor (huésped). Se divide en dos grandes grupos: agudo y crónico. Sus manifestaciones clínicas son diversas, dadas por el compromiso variable de piel, hígado, tracto gastrointestinal, entre otros. Las lesiones cutáneas suelen ser el hallazgos más frecuente tanto en la forma aguda como crónica. Dada la existencia de múltiples procesos patológicos que pueden simular una EIDCH, su diagnóstico requiere, además de un alto índice de sospecha, el estudio histológico y el seguimiento cercano de los pacientes. Dado que cada vez son más frecuentes los trasplantes de médula ósea, así como sus manifestaciones más habituales y precoces ocurren en la piel, es muy importante para los dermatólogos estar familiarizados con este cuadro clínico.

Survival and graft versus host disease in first 100 patients undergoing allogeneic peripheral blood stem cell transplantation: a single centre experience

To present the survival and evaluate the demographic characteristics as risk factors for acute and chronic graft versus host disease [GvHD] in 100 recipients of HLA identical related allogeneic peripheral blood stem cell transplantation. Indications for transplant were non-malignant and malignant haematological disorders. Bu/Cy conditioning was given for haematological malignancies and b-Thalassaemia major, Cyclophosphamide was given in aplastic anaemia. GvHD prophylaxis was Cyclosporin and Methotrexate. The patients received a median nucleated cell dose of 7.93 108/kg. Of 100 recipients, 72 were males and 28 females. Median age was 13.5 years [range 1.5-44]. There were 65 male and 35 female donors. Median age was 15 years [range 4-45]. Grade-I aGvHD was noted in 18 [18%], Grades-II in 6 [6%], Grade-III in 3 [3%] while Grade-IV in 1 [1%] patients. Diagnosis was found to be a significant risk factor for aGvHD. Kaplan Meyer analysis showed that malignancy, aGvHD, recipients above 14 years of age, female patients and engraftment after 12 days were associated with poor outcome. Of 78 patients alive beyond 100 days, 19 [24%] developed cGvHD. Mean follow up was 466 days [range 30-1766]. Median survival of this cohort of patients was 338 days [mean 479 days, 95% CI 72 - 729]. Incidence of acute and chronic GvHD was similar to published data. Grade of aGvHD, extent of cGvHD, female patients and haematological malignancies were associated with higher rate of aGvHD and a worse outcome

Trasplante de médula ósea / Bone marrow transplantation

El trasplante de médula ósea es actualmente un procedimiento de rutina en el tratamiento de tumores sólidos, neoplasias hematológicas, enfermedades adquiridas no malignas y padecimientos congénitos. Este tipo de tratamiento permite remisiones y sobrevidas a largo plazo entre 50 a 90 por ciento de los casos en general y dependiendo del tipo de padecimiento, las condiciones del enfermo y el estadio de enfermedad habitualmente mortales. El conocimiento cada vez más detallado de la biología de las células hematopoyéticas, la posibilidad de recolectarlas de la sangre periférica mediante procedimientos de eféresis y la facilidad de movilizarlas mediante quimioterpia y factores estimulantes de colonias, permite cada vez mejores resultados y hace el trasplante más sencillo. Por otro lado, el establecimiento de rutinas de profilaxis y tratamiento agresivos contra procesos infecciosos, ha permitido el abatimiento de la morbi-mortalidad peritrasplante aún en pacientes con inmunocompromiso grave, secundario a trasplante alogénico de médula ósea y enfermedad de injerto contra huésped

Scedosporium apiospermum sinusitis after bone marrow transplantation: report of a case

Paciente portador de leucemia mieloide cronica, com irma HLA-compativel foi submetido a transplante alogenico de medula ossea. No dia +90 pos-TMO foi diagnosticado doenca do enxerto contra o hospedeiro (DECH) extensa e iniciado protocolo alternado de imunossupressao com altas doses de ciclosporina A e prednisona. O seguimento ambulatorial foi complicado, com granulocitopenia intermitente e quadros frequentes de sinusite e pneumonia. Um ano apos o transplante, o paciente apresentou rouquidao e voz anasalada. Foi realizada uma biopsia de corda vocal mas nenhum agente infeccioso pode ser identificado. Na diminuicao das doses das drogas imunossupressoras, houve piora da DECH cronica e foi reiniciado esquema de doses altas no dia +550. Tres meses apos, permanecendo o quadro de DECH fora do controle, foi tentado imunossupressao com azatioprina sem sucesso...